Conversely, cathepsin L2 appears to reduce the risk of CHF (OR = 0.922%, 95% CI: 0.859–0.99, p = 0.025) and AF (OR = 0.956%, 95% CI: 0.918–0.996, p = 0.033). This evidence concerns the gene CTSV and congestive heart failure.